

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**REQUEST FOR ACCESS TO AN ABANDONED APPLICATION UNDER 37 CFR 1.14**

In re Application of \_\_\_\_\_

Application Number

09/605599

Filed

Jun 28, 2001

Paper No. #11

I hereby request access under 37 CFR 1.14(a)(1)(iv) to the application file record of the above-identified ABANDONED application, which is not within the file jacket of a pending Continued Prosecution Application (CPA) (37 CFR 1.53(d)) and which is identified in, or to which a benefit is claimed, in the following document (as shown in the attachment):

United States Patent Application Publication No. \_\_\_\_\_, page, \_\_\_\_\_ line \_\_\_\_\_,

United States Patent Number \_\_\_\_\_, column \_\_\_\_\_, line, \_\_\_\_\_ or \_\_\_\_\_

WIPO Pub. No. 02/00212 page \_\_\_\_\_, line \_\_\_\_\_.

**Related Information About Access to Applications Maintained in the Image File Wrapper System (IFW) and Access to Pending Applications in General**

A member of the public, acting without a power to inspect, cannot order applications maintained in the IFW system through the FIU. If the member of the public is entitled to a copy of the application file, then the file is made available through the Public Patent Application Information Retrieval system (Public PAIR) on the USPTO internet web site ([www.uspto.gov](http://www.uspto.gov)). Terminals that allow access to Public PAIR are available in the Public Search Room. The member of the public may also be entitled to obtain a copy of all or part of the application file upon payment of the appropriate fee. Such copies must be purchased through the Office of Public Records upon payment of the appropriate fee (37 CFR 1.19(b)).

For published applications that are still pending, a member of the public may obtain a copy of:

the file contents; the pending application as originally filed; or any document in the file of the pending application.

For unpublished applications that are still pending:

- (1) If the benefit of the pending application is claimed under 35 U.S.C. 119(e), 120, 121, or 365 in another application that has: (a) issued as a U.S. patent, or (b) published as a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of: the file contents; the pending application as originally filed; or any document in the file of the pending application.
- (2) If the application is incorporated by reference or otherwise identified in a U.S. patent, a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of the pending application as originally filed.

Neim PR

Signature

Neim Phe

Typed or printed name

Registration Number, if applicable

204 919 1718

Telephone Number

1-26-10

RECEIVED  
FOR PTO USE ONLY

Approved by: [Signature]

(initials)

File Information Unit

This collection of information is required by 37 CFR 1.11 and 1.14. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. BRING TO: File Information Unit, Room 2E04, 2900 Crystal Drive, Arlington, Virginia.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
3 January 2002 (03.01.2002)

PCT

(10) International Publication Number  
WO 02/00212 A1

(51) International Patent Classification<sup>7</sup>: A61K 31/19, 31/205

(74) Agent: MILLER, Raymond, A.; Benesch, Friedlander, Coplan & Aronoff LLP, 2300 BP Tower, 200 Public Square, Cleveland, OH 44114-2378 (US).

(21) International Application Number: PCT/US01/20887

(22) International Filing Date: 28 June 2001 (28.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/605,599 28 June 2000 (28.06.2000) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): NITROSYSTEMS, INC. [US/US]; Trowbridge House, 512 Telfair Street, Augusta, GA 30901 (US).

(72) Inventor; and


(75) Inventor/Applicant (*for US only*): KAESEMEYER, Wayne, H. [US/US]; 2433 McDowell Street, Augusta, GA 30901 (US).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

[Continued on next page]

(54) Title: CONTROLLED RELEASE ARGININE FORMULATIONS



(57) Abstract: A sustained release formulation of L-arginine alone or in combination with an agent which enhances the biotransformation of L-arginine into NO is described herein. Figure 1A shows a schematic representation of proposed L-arginine dependent and independent pathways.

WO 02/00212 A1